However, these phase II clinical trials did not produce the desired results with respect to investigations of the effects of those agents on NSCLC cells with acquired resistance-inducing EGFR mutations or without EGFR-activating mutations [52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.